Ocugen price target raised to $22 from $15 at Lucid Capital

By TheFly | March 11, 2026, 6:10 AM

Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary Phase 2 data for OCU410 in geographic atrophy, the analyst tells investors in a research note.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on OCGN:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

OCGN

+0.57%

Ocugen Inc

Latest News

Mar-27	Can Ocugen succeed where other gene therapy makers have struggled? OCGN Pharma Voice
Mar-25	Ocugens GA gene therapy garners mixed sentiments on 12-month Phase II readout OCGN Clinical Trials Arena
Mar-24	Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration OCGN -8.57% GlobeNewswire
Mar-23	Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy OCGN GlobeNewswire
Mar-11	Ocugen price target raised to $22 from $15 at Lucid Capital OCGN +29.94% TipRanks
Mar-10	Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? OCGN +6.63% Zacks
Mar-04	Ocugen, Inc. Q4 2025 Earnings Call Summary OCGN +5.38% Moby
Mar-04	Ocugen Q4 Earnings Call Highlights OCGN +5.38% MarketBeat
Mar-04	Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates OCGN +5.38% Zacks
Mar-04	Ocugen: Q4 Earnings Snapshot OCGN +5.38% Associated Press Finance
Mar-04	Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results OCGN +5.38% GlobeNewswire
Mar-03	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone OCGN PR Newswire
Mar-02	Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa OCGN +6.59% GlobeNewswire
Feb-25	Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates OCGN Zacks
Feb-24	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates OCGN +8.54% Zacks

Ocugen price target raised to $22 from $15 at Lucid Capital

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your Finviz experience